Events And

American Diabetes Association Scientific Sessions, June 3-7, 2022, New Orleans, LA

Jun 06, 2022 at 4:30 PM CDT

Oral Presentation: Pemvidutide (ALT-801), a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity

Supporting Materials


Investor Contact

Richard Eisenstadt
Chief Financial Officer



Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail